Preliminary Real-World Results of a Community Pharmacy-Based Intervention in COPD: Evidence From the Chronic Diseases From A to Z Program
Author(s)
Elisabete Carvalho, MSc1, Maria Joao Marques, M.D MSc1, António Teixeira-Rodrigues, phD2, JOSÉ GUERREIRO, BSc2, Maria Cary, MSc2, Joana Pinto, MSc2, Catarina Nunes, MSc2.
1Medical Department, AstraZeneca, Barcarena, Portugal, 2Centre for Health Evaluation & Research, National Association of Pharmacies (CEFAR-IS/ANF), LISBOA, Portugal.
1Medical Department, AstraZeneca, Barcarena, Portugal, 2Centre for Health Evaluation & Research, National Association of Pharmacies (CEFAR-IS/ANF), LISBOA, Portugal.
OBJECTIVES: To describe preliminary demographic and clinical findings from a structured community pharmacy (CPh)-based intervention targeting patients with COPD in Portugal. The intervention comprises: (1) a Disease Awareness and Screening Campaign and (2) a Medication Management and Patient Education Programme for those on fixed-dose triple therapy (FDTT).
METHODS: This real-world observational study is being CPh as part of the national “Chronic Diseases from A to Z”. Adult patients with self-reported COPD were invited to participate during routine pharmacy visits. The screening phase involved structured interviews on demographics, smoking status, comorbidities, dyspnoea severity (mMRC), and current COPD pharmacotherapy. Patients on FDTT were invited to participate in a three-month medication management programme, with two visits (T0 and T3), involving the assessment of drug-related problems, inhalation technique, adherence, mMRC score, and exacerbation history. Interventions included patient education and inhaler technique training. Data were recorded using electronic forms. At this stage, only baseline (T0) data are available. Descriptive statistics were applied and paired with T3 results to assess changes in FDTT group.
RESULTS: As of May 28, 2025, 203 patients were enrolled: 122 (60%) on non-FDTT and 81 (40%) on FDTT. Overall, 51% were female, mean age 66.5 years. The most frequent age group was 65-79 years. Among non-FDTT patients, 53% were female, mean age 64.96 years. Among FDTT patients, 48% were female, mean age 68.85 years. mMRC ≥2 was reported in 45% of non-FDTT patients versus 67% (at T0) of FDTT patients, suggesting greater symptom burden in the FDTT subgroup. Detailed clinical outcomes will be presented at the conference.
CONCLUSIONS: These preliminary results highlight the feasibility of engaging COPD patients in structured pharmaceutical interventions within CPh. Findings support CPh role, both in screening and in providing longitudinal support for chronic disease management in real-world settings.
METHODS: This real-world observational study is being CPh as part of the national “Chronic Diseases from A to Z”. Adult patients with self-reported COPD were invited to participate during routine pharmacy visits. The screening phase involved structured interviews on demographics, smoking status, comorbidities, dyspnoea severity (mMRC), and current COPD pharmacotherapy. Patients on FDTT were invited to participate in a three-month medication management programme, with two visits (T0 and T3), involving the assessment of drug-related problems, inhalation technique, adherence, mMRC score, and exacerbation history. Interventions included patient education and inhaler technique training. Data were recorded using electronic forms. At this stage, only baseline (T0) data are available. Descriptive statistics were applied and paired with T3 results to assess changes in FDTT group.
RESULTS: As of May 28, 2025, 203 patients were enrolled: 122 (60%) on non-FDTT and 81 (40%) on FDTT. Overall, 51% were female, mean age 66.5 years. The most frequent age group was 65-79 years. Among non-FDTT patients, 53% were female, mean age 64.96 years. Among FDTT patients, 48% were female, mean age 68.85 years. mMRC ≥2 was reported in 45% of non-FDTT patients versus 67% (at T0) of FDTT patients, suggesting greater symptom burden in the FDTT subgroup. Detailed clinical outcomes will be presented at the conference.
CONCLUSIONS: These preliminary results highlight the feasibility of engaging COPD patients in structured pharmaceutical interventions within CPh. Findings support CPh role, both in screening and in providing longitudinal support for chronic disease management in real-world settings.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
CO186
Topic
Clinical Outcomes, Epidemiology & Public Health, Real World Data & Information Systems
Topic Subcategory
Clinical Outcomes Assessment
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)